Davis said that the recruitment and selection group, which was chaired by WEHI
Board member, Chris Thomas, and included members from the University of Melbourne and Melbourne Health, was delighted to discover that the best person for the job was not only an Australian, but also a scientist of international renown who is currently the Head of WEHI
's Molecular Medicine Division.
This exciting three party research collaboration among world leaders in this field may increase the chance of translating basic scientific research in apoptosis, the process of programmed cell death, as carried out by our collaborators over recent years, into novel targeted cancer therapeutics," says Dr Julian Clark, Head of Business Development at WEHI
is in the front line of the biotechnology revolution, using advances in genetics, bioinformatics and structural biology to help develop individualised therapies and more effective drugs.
Dr Baell continues, "There was a great meeting of minds between chemists from WEHI
and Bionomics, leading to a significant expansion of the patent portfolio.
au; or Brad Allan, Communications Manager, +61-3-9345-2345, or mobile, +61-403036116, both of WEHI
The IC 50 values for total extract and reference drug (the concentration that inhibits the invasion of the WEHI
164 cells by 50% relative to untreated control) were calculated as 15 and 46 [micro]g/ml, respectively.
au), a company based at the WEHI
Biotechnology Centre in Bundoora, Victoria.
This finding prompted the comparative study of TNF-sensibility in WEHI
164 and fibroblast L929 cells.
The agreement builds on basic scientific research carried out at WEHI
over recent years, specifically regarding the therapeutic potential of regulating the activity of proteins that control the normal and healthy process of cell death called apoptosis.
The new agreement provides an important expansion of the initial license agreement covering patent rights signed by Chemicon, Amrad and WEHI
This new agreement provides an important expansion of the initial license agreement covering LIF patent rights signed by Chemicon, Amrad and WEHI
in 1999 to include additional fields of use in non-therapeutic fields.
MELBOURNE, Australia, March 23 /PRNewswire/ -- Scientists at WEHI
have made a discovery with potentially profound implications for the care of patients, especially those undergoing cancer chemotherapy.